Blog

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Jan 26 • 6 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2022. A full copy of the financial results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise…

Is Now the Best Time To Invest in Equity Crowdfunding Campaigns?

Jan 25 • 6 min read

You’re probably familiar with the concept of crowdfunding through platforms like GoFundMe and Kickstarter… Maybe you’ve even donated to a worthy cause… your friend’s pet project… or a new product you believed in (or maybe you just wanted the free swag that came with coughing up some cash). But crowdfunding has become so much more……

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Jan 25 • 4 min read

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones. GH001 for the treatment of TRD GH001 is our proprietary inhalable mebufotenin (5-MeO-DMT) product candidate. We have recently received initial regulatory and ethical approvals for…

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Jan 25 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday, January 25, 2023. The Small Pharma management team will…

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Jan 25 • 3 min read

Diamond Therapeutics Inc, a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce it has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low-doses of psilocybin for the treatment of generalized anxiety disorder…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548